BACKGROUND: In vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P(450) (CYP) 2D6 enzyme and co-administration of deramciclane and the CYP2D6 probe drug desipramine is possible in clinical practice. OBJECTIVE: To evaluate the effects of deramciclane on CYP2D6 activity as measured by desipramine pharmacokinetics and pharmacodynamics using paroxetine as a positive control for CYP2D6 inhibition. METHODS:Fifteen healthy subjects received either 60 mg deramciclane, 20 mg paroxetine or matched placebo for 8 days in randomized order in this double-blind, cross-over study. On day 8 of each study phase, the subjects received a 100-mg single dose of desipramine. Desipramine and its CYP2D6-dependent metabolite, 2-OH-desipramine, concentrations were measured for 240 h. Measurement of secretion of saliva, Visual Analogue Scale assessment of dryness of mouth and tiredness were carried out on day 7 and day 8 to assess the pharmacodynamic consequences of deramciclane or paroxetine co-administration with desipramine. RESULTS: Repeated administration of deramciclane doubled the AUC of desipramine ( P<0.001), while paroxetine caused a 4.8-fold increase in the AUC of desipramine ( P<0.001). Significant correlations were observed with paroxetine (r(s)=0.84, P<0.001) and deramciclane (r(s)=0.51, P=0.0498) concentrations and the magnitude of increase of desipramine AUC. Both deramciclane and paroxetine decreased the formation of 2-OH-desipramine in the first-pass phase. The AUC ratio of 2-OH-desipramine/desipramine was decreased by 39% ( P<0.001) by deramciclane and by 74% ( P<0.001) by paroxetine. There were no changes in the secretion of saliva during co-administration of desipramine with deramciclane compared with placebo. CONCLUSION: Although deramciclane seems to be a weaker inhibitor of CYP2D6 than paroxetine, dose adjustment of drugs metabolized by CYP2D6 may be needed when used concomitantly with deramciclane.
RCT Entities:
BACKGROUND: In vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P(450) (CYP) 2D6 enzyme and co-administration of deramciclane and the CYP2D6 probe drug desipramine is possible in clinical practice. OBJECTIVE: To evaluate the effects of deramciclane on CYP2D6 activity as measured by desipramine pharmacokinetics and pharmacodynamics using paroxetine as a positive control for CYP2D6 inhibition. METHODS: Fifteen healthy subjects received either 60 mg deramciclane, 20 mg paroxetine or matched placebo for 8 days in randomized order in this double-blind, cross-over study. On day 8 of each study phase, the subjects received a 100-mg single dose of desipramine. Desipramine and its CYP2D6-dependent metabolite, 2-OH-desipramine, concentrations were measured for 240 h. Measurement of secretion of saliva, Visual Analogue Scale assessment of dryness of mouth and tiredness were carried out on day 7 and day 8 to assess the pharmacodynamic consequences of deramciclane or paroxetine co-administration with desipramine. RESULTS: Repeated administration of deramciclane doubled the AUC of desipramine ( P<0.001), while paroxetine caused a 4.8-fold increase in the AUC of desipramine ( P<0.001). Significant correlations were observed with paroxetine (r(s)=0.84, P<0.001) and deramciclane (r(s)=0.51, P=0.0498) concentrations and the magnitude of increase of desipramine AUC. Both deramciclane and paroxetine decreased the formation of 2-OH-desipramine in the first-pass phase. The AUC ratio of 2-OH-desipramine/desipramine was decreased by 39% ( P<0.001) by deramciclane and by 74% ( P<0.001) by paroxetine. There were no changes in the secretion of saliva during co-administration of desipramine with deramciclane compared with placebo. CONCLUSION: Although deramciclane seems to be a weaker inhibitor of CYP2D6 than paroxetine, dose adjustment of drugs metabolized by CYP2D6 may be needed when used concomitantly with deramciclane.
Authors: H Kanerva; O Kilkku; A Helminen; J Rouru; M Scheinin; R Huupponen; I Klebovich; S Drabant; A Urtti Journal: Int J Clin Pharmacol Ther Date: 1999-12 Impact factor: 1.366
Authors: H Kanerva; O Kilkku; E Heinonen; A Helminen; J Rouru; S Tarpila; M Scheinin; R Huupponen; I Klebovich; S Drabant; A Urtti Journal: Biopharm Drug Dispos Date: 1999-10 Impact factor: 1.627
Authors: E P Pälvimäki; H Majasuo; M Kuoppamäki; P T Männistö; E Syvälahti; J Hietala Journal: Psychopharmacology (Berl) Date: 1998-03 Impact factor: 4.530
Authors: Magnus Christensen; Gunnel Tybring; Kazuo Mihara; Norio Yasui-Furokori; Juan Antonio Carrillo; Sara I Ramos; Katarina Andersson; Marja-Liisa Dahl; Leif Bertilsson Journal: Clin Pharmacol Ther Date: 2002-03 Impact factor: 6.875
Authors: H Kanerva; H Vilkman; K Någren; O Kilkku; M Kuoppamäki; E Syvälahti; J Hietala Journal: Psychopharmacology (Berl) Date: 1999-07 Impact factor: 4.530
Authors: J Alderman; S H Preskorn; D J Greenblatt; W Harrison; D Penenberg; J Allison; M Chung Journal: J Clin Psychopharmacol Date: 1997-08 Impact factor: 3.153
Authors: Robert Z Harris; Margaret Salfi; Ed Posvar; David Hoelscher; Desmond Padhi Journal: Eur J Clin Pharmacol Date: 2006-05-08 Impact factor: 2.953
Authors: Walter Krauwinkel; James Dickinson; Marloes Schaddelee; John Meijer; Reiner Tretter; Jeroen van de Wetering; Gregory Strabach; Marcel van Gelderen Journal: Eur J Drug Metab Pharmacokinet Date: 2013-06-01 Impact factor: 2.441